Background No observational studies have evaluated the “real-world” effectiveness of dual
bronchodilation comprising a long-acting β2-agonist plus a long-acting muscarinic …

Introduction Chronic obstructive pulmonary disease (COPD) guidelines recommend
reserving triple therapy of inhaled corticosteroid (ICS), long-acting β2-agonist (LABA) and …

Triple therapy for COPD consists of a long-acting anti-cholinergic bronchodilator, a long-
acting beta-agonist bronchodilator, and an inhaled corticosteroid. Guidelines from the …

Most patients with COPD are recommended to initiate maintenance therapy with a single
long-acting bronchodilator, such as a long-acting muscarinic antagonist or long-acting β2 …

Inhaled bronchodilator medications are central to the management of COPD and are
frequently given on a regular basis to prevent or reduce symptoms. While short-acting …

Purpose Randomized trials report that single-inhaler triple therapy is more effective than
dual bronchodilators at reducing exacerbations in patients with chronic obstructive …

Background Ideally, treatment recommendations for maintenance therapy-naïve patients
with COPD should be based on studies conducted specifically in this population. We have …

Rationale: There is uncertainty on the use of using triple therapy (inhaled
corticosteroids/long-acting β-agonist/long-acting muscarinic antagonist) inhaler therapy for …

This real-world study compared the effectiveness of triple therapy (TT; long-acting
muscarinic antagonists (LAMAs)/long-acting inhaled β-agonists (LABAs)/inhaled …

The incidence of chronic obstructive pulmonary disease (COPD) is rising in the United
States, and the disease represents a significant source of morbidity and mortality. Primary …